# Cyclerion Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Cyclerion Therapeutics, Inc.). ## Overview Cyclerion Therapeutics is a U.S.-based biopharmaceutical company focused on building a new pipeline for neuropsychiatric diseases. After divesting legacy assets, it is now centered on developing an individualized therapy for treatment-resistant depression and selectively monetizing remaining soluble guanylate cyclase assets through licensing and option transactions. ## Products & services • Individualized therapy for treatment-resistant depression (TRD) • Licensing of neuropsychiatric therapeutic intellectual property • Option agreements for olinciguat and related legacy assets • Purchase/sale of development materials and other asset transactions • Legacy soluble guanylate cyclase (sGC) stimulator clinical assets - **TRD pipeline development** (10%) — Development of an individualized therapy candidate for treatment-resistant depression. - **Licensing and option revenue** (60%) — Upfront fees, extension fees, and reimbursements from licensing and option agreements. - **Asset sales and development materials** (30%) — Sales of development materials and other transaction-based monetization of legacy assets. - Individualized therapy program for treatment-resistant depression (TRD) - Licensing of TRD-related intellectual property from MIT - Option and license transactions for olinciguat - Sale of additional development materials to partners - Legacy soluble guanylate cyclase (sGC) stimulator assets ## Customers Cyclerion’s direct customers are primarily pharmaceutical and biotech counterparties that license or option its assets, rather than end patients. Its eventual therapeutic customers would be physicians and healthcare systems treating patients with treatment-resistant depression, but near-term revenue is driven by business development transactions with partners. - **Pharmaceutical and biotech partners** (primary) — Buy or option legacy assets and development materials to advance their own pipelines or evaluate licensing rights. - **Academic IP licensors** (secondary) — Provide foundational intellectual property for the TRD program, enabling Cyclerion to build a new clinical asset. - **Future prescribers and treatment centers** (emerging) — Would adopt the TRD therapy if approved, driving eventual commercial demand. - Pharma/biotech partners licensing olinciguat and related assets - Counterparties paying option fees and reimbursements - MIT as an IP licensor for the TRD program - Future prescribers treating patients with TRD - Patients with severe neuropsychiatric disease as the end market ## Geography Cyclerion is headquartered in the United States and its reported transactions and cash management are U.S.-centric. The company’s near-term business is driven by domestic corporate development, licensing, and financing activity, while future commercialization would likely depend on broader U.S. and international regulatory pathways. - Headquartered in the United States - Reported revenue comes from U.S.-based partner transactions - Cash is held in U.S. government money market funds - Future TRD commercialization would likely start in the U.S. - International exposure is currently limited ## Strategy Cyclerion is repositioning itself around a single foundational TRD program while reducing operating expense and preserving optionality from legacy assets. The company is also using licensing, option agreements, and capital raises to fund development and extend runway. - **Advance the TRD program** (short-term) — A focused clinical asset can become the company’s core value driver and commercial foundation. - **Monetize legacy assets** (short-term) — Option and license transactions can generate non-dilutive cash while the new pipeline is built. - **Strengthen financing capacity** (short-term) — The company needs external capital to fund operations and development. - Build a new pipeline around treatment-resistant depression - Use MIT-licensed IP as the foundation for the TRD program - Monetize legacy sGC assets through option and license deals - Reduce operating expenses to preserve cash - Access capital markets through shelf registration and financings ## Risks Cyclerion remains a development-stage company with limited revenue, so its ability to continue operations depends on financing and transaction activity. Clinical, regulatory, and partnering risks are high because the company is building a new pipeline while still monetizing legacy assets, and success is uncertain in both areas. - **Liquidity and going-concern risk** [critical] — The company has minimal unrestricted cash and depends on capital markets and partner transactions to fund operations. - **Clinical development failure** [high] — The TRD program is still in development and may not demonstrate safety, efficacy, or differentiation. - **Partner and asset monetization uncertainty** [high] — Revenue currently depends on option fees, reimbursements, and asset sales that may not recur. - **Dilution from equity financing** [medium] — Funding needs may require issuing common stock or other securities. - Going-concern and financing risk due to low cash balances - Clinical development risk for the TRD program - Partnering risk on legacy asset monetization - Regulatory risk for neuropsychiatric drug development - Dilution risk from future equity financing ## Accounting Cyclerion’s reported revenue is transaction-based, so timing of delivery, option fees, and reimbursements can create quarter-to-quarter volatility. Research and development costs are expensed as incurred, while nonrefundable advance payments are capitalized until goods or services are received, making accrual judgments important for reported results. - **Revenue recognition for option and purchase agreements** — Affects quarterly comparability and reported top-line volatility - **R&D expense accruals** — Can affect operating loss and prepaid/accrued balances - **Capitalization of advance payments** — Influences balance sheet assets and near-term expense recognition - **Going-concern assessment** — Important for solvency and disclosure risk - Revenue recognition depends on delivery, option fees, and reimbursements - Quarterly revenue can swing with one-off partner transactions - R&D is expensed as incurred, affecting operating loss timing - Advance payments are capitalized until services or goods are received - Cash equivalents are held in highly rated short-duration instruments --- *Last updated: 2026-04-28T20:00:04.081808+00:00*